We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Computer Models Help Explain How Tumors Evolve

By LabMedica International staff writers
Posted on 09 Sep 2015
Cancer researchers used computer modeling to create three-dimensional simulations of tumors developing over time in order to explain why the tumor mass is almost exclusively composed of one type of cell while a similar mass of normal tissue would be composed of many cell types.

Most cancers in humans are large, measuring centimeters in diameter, and composed of many billions of cells. More...
An equivalent mass of normal cells would be highly heterogeneous as a result of the mutations that occur during each cell division. What is remarkable about cancers is that virtually every cell within a large tumor often contains the same core set of genetic alterations, with heterogeneity confined to mutations that emerge late during tumor growth. How such alterations expand within the spatially constrained three-dimensional architecture of a tumor, and come to dominate a large, pre-existing lesion, has been unclear.

An international team of investigators from the University of Edinburgh (United Kingdom), Harvard University (Cambridge, MA, USA), and Johns Hopkins University (Baltimore, MD, USA) developed computer models to describe how short-range dispersal and cell turnover could account for rapid cell mixing inside the tumor during its evolution.

The investigators reported in the August 26, 2015, online edition of the journal Nature that a small selective advantage of a single cell within a large tumor would allow the descendants of that cell to replace the precursor mass in a clinically relevant time frame. They also demonstrated that the same mechanisms could be responsible for the rapid onset of resistance to chemotherapy.

The investigators stated that their model not only provided insights into spatial and temporal aspects of tumor growth, but also suggested that targeting short-range cellular migratory activity could have marked effects on tumor growth rates.

First author Dr. Bartlomiej Waclaw, a researcher in the school of physics and astronomy at the University of Edinburgh, said, "Computer modeling of cancer enables us to gain valuable insight into how this complex disease develops over time and in three dimensions."

Related Links:

University of Edinburgh
Harvard University
Johns Hopkins University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.